Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 2, 2007, Pages 301-304

  García Castillo, María ^a   Morosini, María Isabel ^a   Valverde, Aránzazu ^a   Almaraz, Felisa ^a   Baquero, Fernando ^a   Cantón, Rafael ^a   del Campo, Rosa ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

CF; Minimum biofilm inhibitory concentrations; S. pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPLANKTON; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIOFILM; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC RESISTANCE; BLOOD; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STREPTOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BIOFILMS; BLOOD; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 33947513992     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl482     Document Type: Article

References (10)

1. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999; 284: 1318-22.
2. Donlan R, Piede MJA, Hayes CD et al. Model system for growing and quantifying Streptococcus pneumoniae biofilms in situ and in real time. Appl Environ Microbiol 2004; 70: 4980-8.
3. Singh PK, Schaefer AL, Parsek MR et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-4.
4. Hill D, Rose B, Pajkos A et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 2005; 43: 5085-90.
5. Lee B, Haagensen JA, Ciofu O et al. Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 2005; 43: 5247-55.
6. del Campo R, Morosini MI, de la Pedrosa EG et al. Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. J Clin Microbiol 2005; 43: 2207-14.
7. Allegrucci M, Hu FZ, Shen K et al. Phenotypic characterization of Streptococcus pneumoniae biofilm development. J Bacteriol 2006; 188: 2325-35.
8. Budhani RK, Struthers JK. The use of Sorbarod biofilms to determine the antimicrobial susceptibilities of a strain of Streptococcus pneumoniae. J Antimicrob Chemother 1997; 40: 601-2.
9. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
10. Moskowitz SM, Foster JM, Emerson J et al. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42: 1915-22.